News NICE changes its mind on BMS' lymphoma cell therapy Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.
News Boehringer eyes third quarter FDA verdict for oral HER2 drug Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
News BMS study of Opdualag in adjuvant melanoma ends in failure Bristol Myers Squibb has reported disappointing results for its checkpoint inhibitor combination Opdualag in an adjuvant melanoma study.
News Merck confirms its interest in buying SpringWorks Merck KGaA has acknowledged that it is in talks to buy US cancer SpringWorks, but cautioned there is no guarantee a deal will be forthcoming.
News MSD starts pivotal trial of ROR1 drug in first-line lymphoma MSD has started a phase 3 trial of ROR1-directed ADC zilo-V as a treatment for previously untreated diffuse large B-cell lymphoma.
News Pressure relieved on AZ as details of Chinese probe emerge AstraZeneca's exposure to liability in a Chinese investigation into illegal drug imports appears to be much less than had been feared.
News Bayer's Kerendia on course for NHS use in heart failure Up to 280,000 people with heart failure could soon be eligible for NHS treatment with Bayer's Kerendia, following new NICE guidance.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.